What a stability program has to test

The date is an output, and so is the storage instruction

One sentence in the federal manufacturing rules sets up everything else about dating.

There has to be a written testing program designed to assess the stability characteristics of drug products. The results are used in determining appropriate storage conditions and expiration dates.

Notice that both come out of the same program. The temperature on the carton and the date on the carton are two answers from one body of work, which is why they are meant to be read together rather than separately.

The rule then adds a line that is easy to skim past. The written program shall be followed. A program that exists on paper and is not run is a failure of this section in its own right.

What follows is a list of five things the program has to include, and they are more specific than most people expect.

How much and how often is supposed to be a statistics question

The first required element is sample size and test intervals.

They have to be based on statistical criteria for each attribute examined, to assure valid estimates of stability.

Two phrases in that sentence carry the weight. For each attribute examined means potency and appearance and anything else being tracked can each need their own schedule. And valid estimates of stability is a standard about the design of the study rather than about the result.

The practical consequence is that a stability claim is only as good as its sampling plan. Testing one vial at one time point is data, but it is not the program this section describes.

The samples on test have storage conditions of their own

The second element is short and it is the one people forget.

The program has to include storage conditions for samples retained for testing.

That is a rule about the study, not about the product. Samples held back to be tested later have to be kept under stated conditions, because otherwise the later result describes how the samples were stored rather than how the product ages.

It is the same logic that makes a control group necessary in a trial. If the thing being measured drifts for a second reason, the measurement stops meaning what it says.

Reliable, meaningful, and specific

The third element is three adjectives applied to the test methods, and each one rules out a different failure.

The methods have to be reliable, meaningful, and specific.

Specific is the demanding one. A method that measures the intact molecule but cannot distinguish it from a breakdown product will report a comfortable number while the product degrades.

That is not a hypothetical for a peptide. A separate article on this site covers what a purity number from a common analytical method does and does not establish, and the gap it describes is exactly the gap this word closes.

The same container it is actually sold in

The fourth element is the most quotable sentence in the section.

The program has to include testing of the drug product in the same container-closure system as that in which the drug product is marketed.

A container-closure system is the vial, the stopper and the seal together. The requirement exists because a molecule interacts with what it is sitting in. A stopper can absorb material, a seal can admit air, and glass can shed particles.

The consequence for a reader is direct. A stability figure generated in one container does not automatically carry to a different one, even for the same compound at the same strength.

This is the requirement that separates a program from a data sheet. The storage numbers circulating for research peptides generally come from chemical supplier documents and published literature rather than from a program of this shape. A separate article on this site traces where those numbers originate.

Two tests for anything that gets mixed before use

The fifth element is the one that matters most on an injectable prepared from a powder.

The program has to include testing of drug products for reconstitution at the time of dispensing, as directed in the labeling, as well as after they are reconstituted.

That is two separate measurements on one product. One describes the material as it is handed over. The other describes it in solution.

The rule treats the powder and the liquid as different things to be tested, because they behave differently and they age differently.

The labeling counterpart of that requirement lives in a different section, and the article on beyond-use dating covers it. This section is about the testing that has to happen before any date can be printed.

A tentative date, and the obligation attached to it

The section then addresses how many batches, and what happens when the full study is not finished.

An adequate number of batches of each drug product has to be tested to determine an appropriate expiration date, and a record of that data has to be kept.

Accelerated studies may be used to support a tentative expiration date. They are combined with basic stability information on the components, the drug product and the container-closure system.

Two conditions come attached, and they are stated together. Full shelf life studies are not available, and they are being conducted.

The rule then closes the loop. Where an accelerated study projects a tentative date beyond what actual shelf life studies support, stability studies have to continue. Testing goes on at appropriate intervals, until the tentative date is verified or the appropriate date is determined.

So a projected date is a commitment to keep testing rather than a shortcut around it.

Where the section stops

Two carve-outs sit at the end, and they are worth knowing because they show the rule has edges rather than exceptions by argument.

Homeopathic drug products get a different and lighter requirement. There has to be a written assessment of stability, based at least on testing or examination for compatibility of the ingredients. It also rests on marketing experience indicating no degradation over the normal or expected period of use. The evaluation still has to use the same container-closure system in which the product is marketed.

Allergenic extracts labeled with no United States standard of potency are exempt from the section entirely.

Neither carve-out reaches a compounded injectable. They are listed here because a rule with two narrow named exemptions is a rule that otherwise applies, and knowing that is useful when a page implies the requirement is optional.

Who these rules bind, and what a buyer can ask

The regulation states its own reach. It contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals.

Whether a given compounder is held to it depends on which part of the compounding statute that facility operates under, because the two categories are exempted from different lists of requirements. That comparison is the subject of the article on what a compounding exemption actually exempts.

So this is a reference point rather than a promise about any seller. It describes what stands behind a date when somebody is required to generate one.

Three questions follow from it. Was the number generated in the container the product is sold in, since that is a stated requirement rather than a nicety. Does the figure cover the solution as well as the powder, because those are two required tests. And is the date supported by completed studies or projected from an accelerated one, which is a different kind of claim with an ongoing obligation behind it.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations Section 211.166, Stability testing, read in full including the five required elements of the written program, the accelerated-study proviso supporting a tentative expiration date and the obligation to continue testing until it is verified, and the homeopathic and allergenic-extract exemptions — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. Title 21 Code of Federal Regulations Section 211.1, Scope, stating that the part contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026